Board of Directors

Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

Ben Cheng is the Chief Executive Officer and Director of Artisan. He is also currently the Managing Partner at C Ventures, where he leads its sought-after deals and actively engages in major venture capital and private equity investments across the sectors of healthcare, consumer and technology. Named as “China’s Top 20 Most Outstanding Investor” by Lieyun.com in 2020, Mr. Cheng has helped execute many investments in the aforementioned “unicorns”, such as Xpeng Motors, NIO, JD Logistics, Gojek, FTA, Xiaohongshu and Pony.ai.. Mr. Cheng is also a member of the Advisory Committee of Vertex SEA Fund, a subsidiary of Temasek Holdings, and a member of Venture Committee of Hong Kong Venture Capital and Private Equity Association.
 
Mr. Cheng has also served as a General Manager at New World Development since March 2016 and the Chief Investment Officer of Private Equity Department at ARTA TechFin Corporation Ltd since July 2021. Prior to his current roles, Mr. Cheng was an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank. Mr. Cheng holds a bachelor’s degree in Quantitative Finance with honors from the Chinese University of Hong Kong.

Dr. Cui Zhanfeng serves as a Director of Prenetics. Dr. Cui is also on the Board of Oxsed Limited, a wholly owned subsidiary of Prenetics, and Director of two spin-off technology companies from the University of Oxford’s Institute of Biomedical Engineering, Oxford MEStar Limited and Oxford SimCell Limited.

Dr. Cui is the Donald Pollock Professor of Chemical Engineering at the University of Oxford, a Fellow of Hertford College, and the Director of Oxford Suzhou Centre for Advanced Research. He received his Doctor of Science from the University of Oxford in 2009, a M.A. from Keble College, Oxford in 1994, a M.Sc and a Ph.D. in chemical engineering from Dalian University of Technology in China in 1984 and 1987, and a B.Sc in chemical engineering from Inner Mongolia Polytechnic University in 1982. 

Amongst his accolades, Dr. Cui received the 2010 Basil Brennan Medal from the Institution of Chemical Engineers, the Global Research Award from the Royal Academy of Engineering in 2005 and the Foresight Award in 1999. In 2021, Dr. Cui was elected as a Foreign Member of the Chinese Academy of Engineering and is a Fellow of the Institution of Chemical Engineers, the American Institute of Medical and Biological Engineering and the Royal Academy of Engineering. 

Ian Ying Woo serves as an Independent Director of Prenetics. Mr. Woo is also the Executive Director, President and CFO of Everest Medicines, a biopharma platform focused on bringing innovative medicines to Greater China and Asian emerging markets. 

Mr. Woo was a Managing Director at C-Bridge Capital, a healthcare-dedicated private equity firm, and a Managing Director in the global healthcare group at Lazard, where he worked with numerous global life sciences companies and led the firm’s healthcare efforts in Greater China. 

Mr. Woo received a MBA from Columbia University Business School in 2003, a M.Sc in Molecular and Cellular Biology from Columbia University in 1998 and a B.Sc in Biology from Tufts University in 1994.

Chiu Wing Kwan (Winnie) serves as an Independent Director of Prenetics. Ms. Chiu is also the President and Executive Director of Dorsett Hospitality International, the Executive Director of Far East Consortium International Limited, and the Chairperson of AGORA Hospitality Group Co., Ltd. 

Ms. Chiu serves on numerous social committees in various capacities, including the Greater Bay Area Homeland Youth Community Foundation, the Better Hong Kong Foundation, the Community Chest, Our Hong Kong Foundation, the Federation of Hong Kong Hotel Owners and Hong Kong-Japan Business Co-Operation Committee. Ms. Chiu is an active philanthropist primarily focused on arts and education. She is Chairman of the Hong Kong Art School and Joint President of the Society of the Academy for Performing Arts. She also holds positions on the Hong Kong Arts Development Council and on Boards at Hong Kong University and Chinese University of Hong Kong. 

Amongst her accolades, Ms. Chiu received Honorary Fellowships from the Hong Kong Academy for Performing Arts and the Vocational Training Council in Hong Kong. She also received the World Outstanding Chinese Youth Award in 2016 and was nominated for Asia’s Power Businesswomen by Forbes in 2014. Ms. Chiu holds a B.Sc from King’s College, University of London.